Jump to navigation Jump to search
Clinical data
Trade namesLyxumia
[[Regulation of therapeutic goods |Template:Engvar data]]
Routes of
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass4858.49 g/mol
3D model (JSmol)

WikiDoc Resources for Lixisenatide


Most recent articles on Lixisenatide

Most cited articles on Lixisenatide

Review articles on Lixisenatide

Articles on Lixisenatide in N Eng J Med, Lancet, BMJ


Powerpoint slides on Lixisenatide

Images of Lixisenatide

Photos of Lixisenatide

Podcasts & MP3s on Lixisenatide

Videos on Lixisenatide

Evidence Based Medicine

Cochrane Collaboration on Lixisenatide

Bandolier on Lixisenatide

TRIP on Lixisenatide

Clinical Trials

Ongoing Trials on Lixisenatide at Clinical

Trial results on Lixisenatide

Clinical Trials on Lixisenatide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lixisenatide

NICE Guidance on Lixisenatide


FDA on Lixisenatide

CDC on Lixisenatide


Books on Lixisenatide


Lixisenatide in the news

Be alerted to news on Lixisenatide

News trends on Lixisenatide


Blogs on Lixisenatide


Definitions of Lixisenatide

Patient Resources / Community

Patient resources on Lixisenatide

Discussion groups on Lixisenatide

Patient Handouts on Lixisenatide

Directions to Hospitals Treating Lixisenatide

Risk calculators and risk factors for Lixisenatide

Healthcare Provider Resources

Symptoms of Lixisenatide

Causes & Risk Factors for Lixisenatide

Diagnostic studies for Lixisenatide

Treatment of Lixisenatide

Continuing Medical Education (CME)

CME Programs on Lixisenatide


Lixisenatide en Espanol

Lixisenatide en Francais


Lixisenatide in the Marketplace

Patents on Lixisenatide

Experimental / Informatics

List of terms related to Lixisenatide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Lixisenatide (intended trade name Lyxumia) is a once-daily injectable GLP-1 receptor agonist discovered by Zealand Pharma A/S of Denmark and licensed and developed by Sanofi.[1] As of September 2010 it is in clinical trials for diabetes.[2] Lixisenatide was accepted for review by the US FDA on February 19, 2013, and approved by the European Commission on February 1, 2013.[3] On September 12, 2013, Sanofi delayed the approval process in the US, citing internal data from a cardiovascular risk study. The drug will likely be resubmitted for approval in 2015.

GLP-1 is a naturally-occurring peptide that is released within minutes of eating a meal. It is known to suppress glucagon secretion from pancreatic alpha cells and stimulate insulin secretion by pancreatic beta cells. GLP-1 receptor agonists are in development as an add-on treatment for type 2 diabetes and their use is endorsed by the European Association for the Study of Diabetes, the American Diabetes Association, the American Association of Clinical Endocrinologists and the American College of Endocrinology.

The GetGoal phase III clinical program will provide data for lixisenatide in adults with type 2 diabetes treated with various oral anti-diabetic agents or insulin. With ten trials in the program, GetGoal started in May 2008 and has enrolled more than 4,300 patients. To date, GetGoal-X, GetGoal-L, GetGoal-L Asia, GetGoal-Mono, GetGoal-S and GetGoal-F1 have reported positive top-line results supporting efficacy and safety for lixisenatide.


Lixisenatixe has been described as "des-38-proline-exendin-4 (Heloderma suspectum)-(1–39)-peptidylpenta-L-lysyl-L-lysinamide", meaning it is derived from the first 39 amino acids in the sequence of the peptide exendin-4, found in the Gila monster (Heloderma suspectum), omitting proline at position 38 and adding six lysine residues. Its complete sequence is:[4]



  1. Christensen, M; Knop, FK; Holst, JJ; Vilsboll, T (2009). "Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus". IDrugs : the investigational drugs journal. 12 (8): 503–13. PMID 19629885.
  2. "Positive Phase III Data for Two Separate Type 2 Diabetes Therapies Reported at ESAD". Genetic Engineering & Biotechnology News. 20 September 2010.
  3. "Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA". Newsire. 19 February 2013.
  4. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 61" (PDF). WHO Drug Information. 23 (1): 66f. 2009.

Template:Oral hypoglycemics